FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074870601> ?p ?o ?g. }

• W2074870601 endingPage "619" @default.
• W2074870601 startingPage "613" @default.
• W2074870601 abstract "This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients.Patients were randomly assigned to D 30 mg m(-2) as intravenous infusion (i.v.) and EPI 30 mg m(-2) i.v. every week (D/EPI arm), or D 70 mg m(-2) i.v. every 3 weeks and oral P 5 mg twice daily (D/P arm). Chemotherapy was administered until disease progression or unacceptable toxicity.A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The median progression-free survival (PFS) was 11.1 months (95% CI 9.2-12.6 months) in the D/EPI arm and 7.7 months (95% CI 5.7-9.4 months) in the D/P arm (P=0.0002). The median survival was 27.3 months (95% CI 22.1-30.8 months) in the D/EPI arm and 19.8 months (95% CI 14.4-24.8 months) in the D/P arm (P=0.003). Both regimens were generally well tolerated.The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P." @default.
• W2074870601 created "2016-06-24" @default.
• W2074870601 creator A5009629939 @default.
• W2074870601 creator A5011726651 @default.
• W2074870601 creator A5013852734 @default.
• W2074870601 creator A5024088000 @default.
• W2074870601 creator A5025580644 @default.
• W2074870601 creator A5026259658 @default.
• W2074870601 creator A5036125918 @default.
• W2074870601 creator A5047413929 @default.
• W2074870601 creator A5056120002 @default.
• W2074870601 creator A5064666635 @default.
• W2074870601 creator A5081228381 @default.
• W2074870601 creator A5089715372 @default.
• W2074870601 date "2011-02-01" @default.
• W2074870601 modified "2023-10-08" @default.
• W2074870601 title "Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study" @default.
• W2074870601 cites W1893347245 @default.
• W2074870601 cites W1932317695 @default.
• W2074870601 cites W1947168884 @default.
• W2074870601 cites W1968310949 @default.
• W2074870601 cites W1972315151 @default.
• W2074870601 cites W1985877415 @default.
• W2074870601 cites W2020258315 @default.
• W2074870601 cites W2045927420 @default.
• W2074870601 cites W2064057880 @default.
• W2074870601 cites W2072184463 @default.
• W2074870601 cites W2076709420 @default.
• W2074870601 cites W2080439368 @default.
• W2074870601 cites W2084518320 @default.
• W2074870601 cites W2086354109 @default.
• W2074870601 cites W2103090668 @default.
• W2074870601 cites W2111199038 @default.
• W2074870601 cites W2113092779 @default.
• W2074870601 cites W2115962082 @default.
• W2074870601 cites W2120292596 @default.
• W2074870601 cites W2124482409 @default.
• W2074870601 cites W2139248078 @default.
• W2074870601 cites W2155679349 @default.
• W2074870601 cites W2162827359 @default.
• W2074870601 cites W2167571044 @default.
• W2074870601 doi "https://doi.org/10.1038/bjc.2011.5" @default.
• W2074870601 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3049601" @default.
• W2074870601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21285986" @default.
• W2074870601 hasPublicationYear "2011" @default.
• W2074870601 type Work @default.
• W2074870601 sameAs 2074870601 @default.
• W2074870601 citedByCount "12" @default.
• W2074870601 countsByYear W20748706012012 @default.
• W2074870601 countsByYear W20748706012014 @default.
• W2074870601 countsByYear W20748706012015 @default.
• W2074870601 countsByYear W20748706012016 @default.
• W2074870601 countsByYear W20748706012018 @default.
• W2074870601 countsByYear W20748706012021 @default.
• W2074870601 crossrefType "journal-article" @default.
• W2074870601 hasAuthorship W2074870601A5009629939 @default.
• W2074870601 hasAuthorship W2074870601A5011726651 @default.
• W2074870601 hasAuthorship W2074870601A5013852734 @default.
• W2074870601 hasAuthorship W2074870601A5024088000 @default.
• W2074870601 hasAuthorship W2074870601A5025580644 @default.
• W2074870601 hasAuthorship W2074870601A5026259658 @default.
• W2074870601 hasAuthorship W2074870601A5036125918 @default.
• W2074870601 hasAuthorship W2074870601A5047413929 @default.
• W2074870601 hasAuthorship W2074870601A5056120002 @default.
• W2074870601 hasAuthorship W2074870601A5064666635 @default.
• W2074870601 hasAuthorship W2074870601A5081228381 @default.
• W2074870601 hasAuthorship W2074870601A5089715372 @default.
• W2074870601 hasBestOaLocation W20748706011 @default.
• W2074870601 hasConcept C121608353 @default.
• W2074870601 hasConcept C126322002 @default.
• W2074870601 hasConcept C126894567 @default.
• W2074870601 hasConcept C141071460 @default.
• W2074870601 hasConcept C2776694085 @default.
• W2074870601 hasConcept C2776755627 @default.
• W2074870601 hasConcept C2778720950 @default.
• W2074870601 hasConcept C2780192828 @default.
• W2074870601 hasConcept C2780835546 @default.
• W2074870601 hasConcept C2781190966 @default.
• W2074870601 hasConcept C31760486 @default.
• W2074870601 hasConcept C71924100 @default.
• W2074870601 hasConcept C90924648 @default.
• W2074870601 hasConceptScore W2074870601C121608353 @default.
• W2074870601 hasConceptScore W2074870601C126322002 @default.
• W2074870601 hasConceptScore W2074870601C126894567 @default.
• W2074870601 hasConceptScore W2074870601C141071460 @default.
• W2074870601 hasConceptScore W2074870601C2776694085 @default.
• W2074870601 hasConceptScore W2074870601C2776755627 @default.
• W2074870601 hasConceptScore W2074870601C2778720950 @default.
• W2074870601 hasConceptScore W2074870601C2780192828 @default.
• W2074870601 hasConceptScore W2074870601C2780835546 @default.
• W2074870601 hasConceptScore W2074870601C2781190966 @default.
• W2074870601 hasConceptScore W2074870601C31760486 @default.
• W2074870601 hasConceptScore W2074870601C71924100 @default.
• W2074870601 hasConceptScore W2074870601C90924648 @default.
• W2074870601 hasIssue "4" @default.
• W2074870601 hasLocation W20748706011 @default.
• W2074870601 hasLocation W20748706012 @default.
• W2074870601 hasLocation W20748706013 @default.

• next